Ose Immuno receives funding from Bpifrance

(CercleFinance.com) - OSE Immunotherapeutics announces that it has received non-dilutive funding of 8.
4 million euros under the "i-Démo" call for projects of the France 2030 plan, operated by Bpifrance on behalf of the French government.

This public funding will support the Phase 3 registration trial of Tedopi®, a neo-epitope-based cancer vaccine, as a second-line treatment for non-small-cell lung cancer in HLA-A2 positive patients with secondary or acquired resistance to anti-PD-(L) immunotherapy.

This innovation will respond to the important medical need of patients suffering from non-small cell lung cancer, in the absence of approved therapeutic options to date after failure of immunotherapies. Following FDA approval of the trial protocol at the beginning of the year, we will be able to start this confirmatory Phase 3 trial in the United States in the next few weeks, and then, once we have obtained approval from
the EMA, in Europe and in particular in France, where a number of clinical sites are planned", said Nicolas Poirier, Chief Executive Officer of Ose
Immunotherapeutics.

Copyright (c) 2024 CercleFinance.com. All rights reserved.